RELMADA THERAPEUTICS, INC.(RLMD)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

RELMADA THERAPEUTICS, INC. (RLMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. RLMD is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of RLMD by reported 13-F value include Jupiter Topco, BlackRock, Squadron Capital Management, based on the most recent SEC filings. RLMD trades on the Nasdaq exchange and files with the SEC under CIK 1553643. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RLMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RELMADA THERAPEUTICS, INC. directly from SEC EDGAR.

Net Income

$-12.9M

RLMD key financials by period

RELMADA THERAPEUTICS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 201410-Q$15.6K$-27.5M—
FY 201310-KT$14.9K$-34.0M—

Institutions holding RLMD

Institutional investors reporting a position in RELMADA THERAPEUTICS, INC. on SEC Form 13F.
InstitutionSharesValueReported
Jupiter Topco11,164,803$77.3M2026-06-30
BlackRock7,426,780$51.4M2026-06-30
Squadron Capital Management7,350,000$50.9M2026-06-30
VR Adviser6,844,305$47.4M2026-06-30
Spruce Street Capital6,391,328$44.2M2026-06-30
ADAGE CAPITAL PARTNERS GP, L.L.C.4,763,158$33.0M2026-06-30
VANGUARD CAPITAL MANAGEMENT4,460,210$30.9M2026-06-30
Jones Hill Capital3,655,075$25.3M2026-06-30
ORBIMED ADVISORS3,631,195$25.1M2026-06-30
STATE STREET2,517,550$17.4M2026-06-30
SEC EDGAR: CIK 1553643 →
RLMD

RELMADA THERAPEUTICS, INC.

RLMD
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-12.91M

EPS (Diluted)

Q2 2026
EDGAR

$-0.11

ROIC

Q2 2026
EDGAR

-29.1%

Top Institutional Holders

as of Q2 2026
$695.74M total
Jupiter Topco LLC
$77.32MNew
BlackRock, Inc.
$51.39M+475.9%
Squadron Capital Management LLC
$50.86M-13.3%
VR Adviser, LLC
$47.36M+41.3%
Spruce Street Capital LP
$44.23M+2.1%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$32.96M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$30.86M+45.0%
Jones Hill Capital LP
$25.29M+966.4%
ORBIMED ADVISORS LLC
$25.13M-23.0%
STATE STREET CORP
$17.42M+605.1%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…